Original Research Paper

Engineered targeting tLyp-1 exosomes as gene therapy vectors for efficient delivery of siRNA into lung cancer cells

Jing Bai, Jialun Duan, Rui Liu, Yafei Du, Qian Luo, Yinuo Cui, Zhanbo Su, Jiarui Xu, Ying Xie, Wanliang Lu*

State Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug System, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

A R T I C L E   I N F O

Article history:
Received 27 January 2019
Revised 12 April 2019
Accepted 27 April 2019
Available online 6 May 2019

Keywords:
Targeting tLyp-1-exosomes
Engineering
Transfection
Gene therapy
Lung cancer

A B S T R A C T

Natural exosomes can express specific proteins and carbohydrate molecules on the surface and hence have demonstrated the great potentials for gene therapy of cancer. However, the use of natural exosomes is restricted by their low transfection efficiency. Here, we report a novel targeting tLyp-1 exosome by gene recombinant engineering for delivery of siRNA to cancer and cancer stem cells. To reach such a purpose, the engineered tLyp-1-lamp2b plasmids were constructed and amplified in Escherichia coli. The tLyp-1-lamp2b plasmids were further used to transfect HEK293T tool cells and the targeting tLyp-1 exosomes were isolated from secretion of the transfected HEK293T cells. Afterwards, the artificially synthesized siRNA was encapsulated into targeting tLyp-1 exosomes by electroporation technology. Finally, the targeting siRNA tLyp-1 exosomes were used to transfect cancer or cancer stem cells. Results showed that the engineered targeting tLyp-1 exosomes had a nanosized structure (approximately 100 nm) and high transfection efficiency into lung cancer and cancer stem cells. The function verifications demonstrated that the targeting siRNA tLyp-1 exosomes were able to knock-down the target gene of cancer cells and to reduce the stemness of cancer stem cells. In conclusion, the targeting tLyp-1 exosomes are successfully engineered, and can be used for gene therapy with a high transfection efficiency. Therefore, the engineered targeting tLyp-1 exosomes offer a promising gene delivery platform for future cancer therapy.

© 2019 Shenyang Pharmaceutical University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
1. Introduction

Lung cancer remains to be the leading cause of cancer-related deaths worldwide. As one of the two main subtypes, non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers [1]. The major strategy for treatment of lung cancer is a comprehensive approach, including surgical therapy, chemotherapy and radiotherapy. For treatment of NSCLC, chemotherapy plays a critical role as the surgical treatment is only used at the early stage of the cancer. However, clinical studies shows that NSCLC has a very limited response to the chemotherapy [2].

Gene therapy has demonstrating a promising approach for treatment of NSCLC, and it has been simply defined as the genetic modification of cells to produce a therapeutic effect [3]. Gene therapy is also called human gene transfer that is the therapeutic delivery of nucleic acids (DNA or RNA) into a patient’s cells as a drug to treat disease [4,5]. There are several methods by which to achieve gene therapy purpose. One strategy involves the deletion and addition of specific DNA fragments through gene editing. The other one introduces exogenous genes into the cells to cleave specific sequence in the mRNA transcript of the faulty gene, disrupting translation of the faulty mRNA, and hence correcting the expression of the faulty gene [6]. In the last years, a number of approaches have been developed for delivery of nucleic acids aimed at achieving therapeutic purposes, mainly including viral vectors [7], and non-viral vectors [8]. However, viral vectors are toxic and immunogenic while non-viral vectors have low transduction efficiency, and larger particle size, which are easy to induce immune response and to be rapidly cleared by reticuloendothelial system (RES). Therefore, non-immunogenicity, tissue specificity and non-toxicity play an important role in the clinical application of gene delivery vectors.

In the present study, we developed a novel kind of engineered targeting tLyp-1 exosomes for efficient delivery of siRNA into human cancer cells. In this construct, a membrane penetrating peptide tLyp-1 gene was engineered into a kind of exosomes by gene recombinant technique, 3 kinds of siRNA for silencing SOX2 gene were designed and encapsulated into the targeting tLyp-1 exosomes by electroporation technique.

Exosomes are nano-sized membrane vesicles (30–100 nm in diameter) secreted by numerous cell types such as tumor cells, T cells, B cells, dendritic cells (DC), mast cells and epithelial cells. Exosomes have natural properties because they are derived from the fusion of multivesicular bodies (MVBs) with plasma membranes [9]. Exosomes play an important role in cellular communication, especially in immune responses and cancer. When exosomes containing mRNA and microRNA are transferred to recipient cells, the mRNA and microRNA still maintain their functions and change the behavior of recipient cells [10,11]. Despite signal-carrying capacity of exosomes, scientists have paid more attention of their potential in drug delivery for cancer therapy in the last few years. For examples, Sun et al. prepared exosomes loaded with curcumin and showed better solubility and anti-inflammatory bioactivity than the traditional curcumin [12]. Tian et al. loaded hydrophilic compounds doxorubicin into exosomes by electroporation [13]. In addition, exosomes are cell derived nano-scale membrane vesicles that are considered as siRNAs or miRNAs delivering tools to knockdown genes [14]. Current preliminary studies exhibit that the exosome-mediated nucleic acid delivery in vivo does not cause short-term innate immune activation or obvious side effects.

tLyp-1 peptide (amino-acid sequence CGNKKTR), a newly reported hepta-peptide, is a ligand which selectively target to neuropilin1 (NRP1) and to neuropilin2 (NRP2), both which are highly expressed in tumor tissues including non-small cell lung cancer, and serve as the receptor targets in cancer drug delivery systems [15–17]. tLyp-1 is a tumor homing penetrating membrane peptide which can not only target the tumor [18], but also penetrate the tumor blood vessels and stroma to reach deep into the tumor [19]. Therefore, tLyp-1 modified exosomes can be expected to have active-targeting functions and penetrate extensively into tumor parenchyma.

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20–25 base pairs in length, similar to single-stranded microRNA (miRNA) [20]. Both siRNA and miRNA can play the role of RNA interference (RNAi) in live cells. siRNA interferes with the expression of specific genes with complementary nucleotide sequences by degrading mRNA after transcription, thus preventing translation [21]. siRNA is often used to treat a disease caused by abnormally gene expression, such as viral infection and cancer [22].

The objective of the present study was to develop the targeting tLyp-1 exosomes for improving the targeting ability and transfection capability of natural exosomes, and to confirm the function. During the engineering process, a plasmid vector, which encoded the fusion protein of tLyp-1-lamp2b, was firstly designed for transfecting human embryonic kidney HEK293T tool cells. The transfected HEK293T cells were able to express exosome transmembrane proteins (lamp2b) and tLyp-1 targeting peptide, and therefore, the targeting tLyp-1 exosomes were collected from the transfected HEK293T cells supernatants. The targeting tLyp-1 exosomes were used as the gene delivery vector to encapsulate siRNA by an electroporation approach. To verify the function, the targeting siRNA tLyp-1 exosomes were further applied to human non-small cells lung cancer (NSCLC) cells for observing gene silencing efficiency and action effect.

2. Materials and methods

2.1. Materials and cells

The pEGFP-C1 was from Inovogen Technology Co. (Beijing, China). Antibody against lamp2b was purchased from Abcam (Cambridge, UK) and antibody against GAPDH and SOX2 were purchased from Cell Signaling Technology (Beverly, MA, USA). siRNA was synthesized by RiboBio company (Guangzhou, China). Other reagents were from Beijing Chemical Reagents (Beijing, China).
Human cervical cancer Hela cells, human non-small cell lung cancer (NSCLC) A549 cells and human embryonic kidney HEK293T cells were purchased from Institute of Basic Medical Science, Chinese Academy of Medical Science (Beijing, China). Hela cells and HEK293T cells were cultured in Dulbecco’s modified Eagle medium (DMEM) medium (Macgene, Beijing, China) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin (Macgene, Beijing, China). A549 cells were cultured in RPMI-1640 medium (Macgene, Beijing, China) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin (Macgene, Beijing, China). The cells were cultured in humidified atmosphere of 5% CO₂ at 37 °C. The cells for all experiments were in logarithmic phase of growth.

Human NSCLC A549 stem cells were induced and cultured in DMEM-F12 medium supplemented with 2% B27 supplements (Gibco), epidermal growth factor (EGF, 20 ng/ml), basic fibroblast growth factor (bFGF, 20 ng/ml), leukemia inhibitory factor (LIF, 10 ng/ml) and insulin (181.6 ng/ml). Cells were cultured under an atmosphere of 5% CO₂ at 37 °C.

Escherichia coli (i.e., DH5α competent cells) single colony was picked to 5 ml LB liquid medium (Sigma-Aldrich, St. Louis, USA), incubated at 37 °C in 100-200 r/min shaker for 12 h.

2.2. Engineering and transfection of tLyp-1-lamp2b plasmids

Total RNA was extracted from Hela cells using total RNA extraction kit, which was reversely transcribed into cDNA using reverse transcription kit (Solarbio, Beijing, China). tLyp-1 + lamp2b gene was amplified by PCR using cDNA as template, purified and recovered by using gel recovery kit (Solarbio, Beijing, China). The pEGFP-C1 and tLyp-1-lamp2b genes were digested by Bgl II and BamHI I enzymes, then connected by T4 ligase. The connection products were transformed into DH5α competent cells (stored at −80 °C, Thermo Scientific, Waltham, USA) and cultured for 12 h. Single colony was culled for plasmid extraction. Lipofectamine 3000 transfection reagent (Invitrogen, USA) were used to transfect pEGFP-C1 plasmid vector expressing tLyp-1-lamp2b fusion proteins into HEK293T cells.

2.3. Identification of tLyp-1-lamp2b plasmids

A volume of 0.5 μl forward primer, 0.5 μl reverse primer, 0.2 μl primestar, 1 μl template, 10 μl CG buffer, 1.6 μl dNTP and 6.2 μl H₂O, were mixed together on ice and then PCR reaction was performed. The end product DNA was loaded onto 1% agarose gels. After the agarose gels were cooled to about 60 °C (not hot), and then 10,000 × Goodview dye was added in the gels and mixed evenly. The gels were poured into the tray gently. The DNA sample and loading buffer were mixed, and then the mixture was slowly added to the well using a micropipettor. The electrophoresis was performed at 100 V.

2.4. Isolation and purification of exosomes

Exosomes were isolated by differential centrifugation and micro-filtration. Firstly, the HEK293T cells were incubated for 15 h in exosome-free FBS, which had been centrifuged at 100,000 × g before use. The culture supernatants were collected from cell culture medium, centrifuged at 300 × g for 10 min and 2000 × g for 10 min to remove cells, and then 10,000 × g for 30 min to remove cell debris. After ultracentrifugation at 120,000 × g for another 70 min, exosomes were obtained. Exosomes were rinsed with phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 8 mM Na₂HPO₄ and 2 mM KH₂PO₄, pH 7.4), and then ultra-centrifuged again. Afterwards, exosomes were re-dispersed in PBS (pH 7.4). The protein concentrations of the exosomes suspensions were determined using BCA assays (Thermo Scientific, Waltham, USA). All procedures were performed at 4 °C.

2.5. Encapsulation of siRNA by exosomes

To encapsulate siRNA into the exosomes, 50 μg Cy3-siRNA and 100 μg exosomes were mixed together in 200 μl electroporation buffer. The exosomes were electro transfected at 400 V in 96-well plates using X-porator H1 electroporation apparatus (Yida, Soochow, China). To ensure that the plasma membranes of the exosomes were fully recovered, the mixture was incubated at 37 °C for 30 min. Free siRNA was removed and encapsulation efficiency of siRNA by exosomes was determined by fluorescence spectrophotometer (emission at 590 nm, and excitation at 550 nm).

2.6. Particle size by NTA measurement

Particle sizes and Brownian motion were measured by nanoparticle tracking analysis (NTA). Purified exosomes (100 ml; 10 ng/ml) were performed on a NanoSight LM10-HSB instrument (A&P Instrument Co., Salisbury, UK). The data of size distribution and Brownian motion were captured and analyzed with the NTA 2.2 Analytical Software Suite.

2.7. Morphology by TEM observation

A transmission electron microscope (TEM, FEI Company, OR, USA) was used to further observe the morphology of the exosomes. Purified exosomes from HEK293T cells were re-suspended in PBS (pH 7.4) and fixed with 2% paraformaldehyde for 0.5 h. A volume of 8 μl mixture was then dropped onto EM grids. After drying for 30 min, exosomes were stained with 1% uranyl acetate twice every 6 min. The dried grids were detected using a transmission electron microscope at 120 kV.

2.8. Cellular uptake by flow cytometry

To estimate cellular uptake qualitatively, cancer cells were seeded into chambered coverslips at a density of 1.5 × 10⁵ cells/well. After incubation for 24 h, the cells were treated with 3, 3′-dioctadecylxocarboxyamine perchlorate (DiO, 5 μM) labelled natural exosomes or targeting tLyp-1 exosomes for another 6 h. The cells were then washed with cold PBS (pH 7.4) three times, and then re-suspended in 300 μl PBS (pH 7.4). DiO fluorescence intensity was measured by FACScan flow cytometer (FACScan, Becton Dickinson, San
Jose, CA, USA) with 10,000 events collected. The excitation was set at 484 nm and the emission was set at 501 nm.

2.9. **mRNA expression by real-time qRT-PCR**

Total RNA was extracted using trizol reagents (Invitrogen, Beijing, China) according to the manufacturer’s protocol. The concentration of extracted RNA was determined with Nano-300 reader (YPH-BIO, Beijing, China). An amount of 500 ng total RNA was then reverse-transcribed into cDNA by PrimeScript RT reagent (Takara Bio Inc., Shiga, Japan). Real time qRT-PCR analysis was performed with CFX96 Opticon (Bio-Rad, Hercules, USA) in 25 μl reaction volume by using the SYBR Prime-Script PCR (Takara Bio Inc., Shiga, Japan). Each experiment was repeated for triplicates. Each gene expression level was normalized to GAPDH mRNA content. Relative quantification was calculated with the 2−ΔΔct method [23].

2.10. **Protein expression by Western blotting**

Cells were seeded into 6-well plates and cultured over 24 h until the density reached 70% confluence. After exposure to different agents at fixed intervals in the presence of 10% FBS, cells were harvested in lysis buffer containing 1 mM phenylmethanesulfonyl fluoride (PMSF), 1 mM dithiothreitol (DTT), 10 μg/ml leupeptin, and 10 μg/ml aprotinin. Cells were then centrifuged at 4 °C for 20 min at 12,000 rpm to remove the precipitated fragments. The protein concentration was measured by Bradford protein assay. Equal amount of total protein was loaded and resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Gels were transferred to PVDF membranes (Millipore Corporation, Temecula, USA) and then blocked with 5% BSA (w/v) for 1 h at room temperature. The membranes were incubated with primary antibodies overnight at 4 °C and then with horseradish peroxidase (HRP) linked secondary antibody at room temperature for 1 h according to the optimized dilution ratio. The blots were visualized with Clarity-ECL Western blotting detection reagents (Thermo, Beijing local agent, China) by following the instructions of the manufacturer.

2.11. **Identification of NSCLC stem cells**

The phenotypes of the NSCLC stem cells were identified by flow cytometry (FCM), including CD44 and CD24. Briefly, NSCLC stem cells and SOX2 gene silenced NSCLC stem cells were collected. Then, the cells were incubated at room temperature for 30 min with anti-human CD44 fluorescein isothiocyanate (FITC)-conjugated antibody (BD, 10 μl per test). The cells were washed with PBS (pH 7.4) twice and resuspended in 300 μl PBS (pH 7.4), and the fluorescence intensity was measured by FCM.

To identify CD24, anti-human CD24 phycoerythrin (PE)-conjugated antibody (BD, Beijing, China; 5 μl per test) were separately added using the procedures described above except for the perforation.

Both NSCLC stem cells and SOX2 gene silenced NSCLC stem cells were incubated with FITC-conjugated mouse IgG or PE-conjugated mouse IgG as isotype controls, respectively. The excitation wavelengths were set at 488 nm for both FITC and PE, and the emission wavelengths were set at 530 nm for both FITC and 564 nm for PE.

2.12. **Statistical analyses**

Data were presented as the mean ± standard deviation (SD). One-way analysis of variance was used to determine significance among groups, after which, post hoc tests with the Bonferroni correction were used for multiple comparisons between individual groups. P < 0.05 was considered significant.

3. **Results and discussion**

3.1. **Engineering of targeting tLyP-1-lamp2b plasmids**

The genes of tLyP-1 and lamp2b were synthesized PCR reaction in forming a combined tLyP-1-lamp2b gene. The tLyP-1-lamp2b gene was mixed with the blank pEGFP-C1 plasmids, digested with Bgl II and BamH I enzymes, and then connected by T4 ligase, thereby producing the pEGFP-C1-tLyP-1-lamp2b plasmids, namely, the targeting tLyP-1-lamp2b plasmids (Fig. 1).

The engineered targeting tLyP-1-lamp2b plasmids are used for further amplifying the plasmids with DH5α competent cells, and for transfecting the tool cells (HEK293T cells). If transfecting, the tool cells will secrete the targeting tLyP-1 exosomes, in which tLyP-1 peptide are expressed on the outer membrane of the exosomes by connecting with the extravesomal N-terminus of lamp2b protein.
3.2. Identification of targeting tLyp-1-lamp2b plasmids

To identify the targeting tLyp-1-lamp2b plasmids, a single colony of the plasmids was selected from the DH5α competent cells, amplified in PCR, and used for colony PCR identification. The result from the bands in the electrophoresis image demonstrated that the parallel samples (1–4) produced a fragment of about 1100 bp, respectively, indicating that the tLyp-1-lamp2b genes were constructed into the plasmids (Fig. 2A). In the images, the bands were bright, without impurity band, demonstrating that there was no by-product, and the colony of plasmids was positive clone.

Moreover, a single colony of the plasmids was selected from the DH5α competent cells, and extracted by the extraction kit for further confirming the existence of tLyp-1-lamp2b gene in the plasmids. The extracting product was then digested by Bgl II/Sal I double enzymes, and used for analysis with electrophoresis. The results from the specific bands in the electrophoresis image further demonstrated that the tLyp-1-lamp2b gene was successfully constructed into the plasmid (Fig. 2B). Besides, the gene of green fluorescence protein probe was also constructed into the plasmids.

In addition, the results of plasmid sequencing (Fig. 2C and Fig. S1) demonstrated that the homology of the sample with the original target DNA sequence reached 99.91%, and the homology of amino acid sequence reached 100%.

Through identifications from the above three aspects, the results fully confirmed that the tLyp-1-lamp2b gene was successfully inserted into the pEGFP-C1 plasmid, indicating a successful engineering of the targeting tLyp-1-lamp2b plasmid.

3.3. Transfection efficiency of targeting tLyp-1-lamp2b plasmids into HEK293T cells

To obtain the targeting tLyp-1 exosomes, the targeting tLyp-1-lamp2b plasmids were transfecting into tool cells (HEK293T cells). The expression of green fluorescent protein was used to validate whether tLyp-1-lamp2b plasmids were expressed in HEK293T cells successfully. The results showed that the transfection efficiency was above 70% (Fig. 3A).
Furthermore, the mRNA and protein levels of lamp2b after transfection at 48 h were assessed using real time qRT-PCR and Western blotting, respectively. In contrast to non-transfected HEK293T cells, the results showed that both the mRNA and protein expressions of lamp2b were evidently up-regulated in the transfected HEK293T cells (Fig. 3B and 3C).

The above results demonstrated that targeting tLyp-1-lamp2b plasmids were successfully transfected into HEK293T tool cells, and the tLyp-1-lamp2b protein was successfully expressed in the tool cells.

In this study, tLyp-1 gene is transfecting with lamp2b gene into the HEK293T cells because lamp2b gene is a specific gene, which expresses on the membrane protein of exosome [24]. Transfection using tLyp-1-lamp2b fusion plasmid can lead to the expression of targeting peptide tLyp-1 on the outer membrane of exosomes, while targeting peptide tLyp-1 modified exosomes can be secreted and collected from the transfected HEK293T cells.

Actually, tLyp-1 peptide is a cell penetration-peptide, which can selectively target both NRP1 and NRP2 receptors that highly express in neoplastic vessels and tumor cells [25]. Accordingly, tLyp-1 modified exosomes can be used for targeting cancer cells, and for increasing the penetration of cancer cells. Such functions are especially useful for delivery of gene because the un-modified natural exosomes often have low transfection efficiency when being used as gene delivery vectors [26].

3.4. Isolation and characterization of natural and targeting tLyp-1 exosomes

The isolation of targeting tLyp-1 exosomes was obtained from the culture supernatants of tLyp-1-lamp2b plasmids transfected or non-transfected HEK293T cells by ultracentrifugation. After 5 times of centrifugations, the purified targeting tLyp-1 exosomes and natural exosomes were isolated from the transfected and non-transfected HEK293T cells, respectively.

The results from NTA demonstrated that the targeting tLyp-1 exosomes were approximately 100 nm in diameter (Fig. 4A). In the diluted solution, targeting tLyp-1 exosomes exhibited an evidently Brownian motion, suggesting that the nano-sized exosomes were not aggregated but well single distributed (Fig. 4B).

The results from TEM observations showed that both natural exosomes and targeting tLyp-1 exosomes (Fig. 4C) were round in shape, and their membrane structures could be clearly observed on the exosomes vesicles. Besides, there were no significant differences in the particle size and in the shape between natural and targeting tLyp-1 exosomes.

To identify cellular uptake, flow cytometry was used for quantitative purpose. The evaluation by flow cytometry revealed the uptake rate of targeting tLyp-1 exosomes was higher than that of natural exosomes in A549 cancer cells (Fig. 4D).
Fig. 4 – Characterization of the engineered targeting tLyp-1 exosomes. (A) Size distribution and movement of targeting tLyp-1 exosomes. The targeting tLyp-1 exosomes were measured by nanoparticle tracking analysis (NTA) with NanoSight LM10-HSB instrument. (B) Image of Brownian motion of the tLyp-1 exosomes in PBS (pH 7.4) solution. The targeting tLyp-1 exosomes were photographed by NTA system. (C) Representative TEM images of natural and engineered exosomes. (a): natural exosomes; (b): targeting tLyp-1 exosomes. (D) Uptake of the engineered targeting tLyp-1 exosomes into A549 cells. Both natural exosomes and engineered exosomes were labeled with DiO dye (green fluorescence). (a): mean fluorescent intensity was measured by FACS. 1: natural exosomes; 2: targeting tLyp-1 exosomes. (b): the quantitative results of fluorescent intensity. Data are presented as mean ± SD (n = 3). *P < 0.05 vs natural exosomes.

Fig. 5 – Functional verification of the targeting siRNA tLyp-1 exosomes in silencing SOX2 gene of human NSCLC cells. (A) Designed 3 kinds of sequences for siRNA according to human SOX2 siRNAs. (B) mRNA expression of SOX2 in A549 cells after treated with lipo3000 carrying siRNA, natural exosomes carrying siRNA or targeting tLyp-1 exosomes carrying siRNA. Real-time qRT-PCR analysis was performed on A549 cells that were treated with lipo3000, natural exosomes or targeting tLyp-1 exosomes which carried 3 kinds of siRNAs, respectively. The results demonstrate that siR2 has the highest silence efficiency. P < 0.05; (a): vs natural exosomes; (b): vs. lipo3000. Data are presented as mean ± SD (n = 3). (C) Images of human NSCLC A549 cells under fluorescence microscope. (a): image of transfected A549 cells with siR2 lipo3000 under fluorescent microscope in bright field; (b): image of transfected A549 cells with the targeting siR2 tLyp-1 exosomes under fluorescent microscope in bright field; (c): image of transfected A549 cells with siR2 lipo3000 under fluorescent microscope in dark field; (d): image of transfected A549 cells with targeting tLyp-1 exosomes under fluorescent microscope in dark field. siRNA (siR2) was labeled with Cy3 and blue was set as an indicator of transfection efficiency by fluorescence microscopy. The results demonstrate a successful transfection in A549 cells using the targeting siR2tLyp-1 exosomes.
As natural exosomes express specific proteins and carbohydrate molecules on the surface, they have been used as drug delivery vectors, which can avoid the phagocytosis of mononuclear phagocyte system in blood circulation after administration [27]. Moreover, nano-sized exosomes can enhance the permeability and retention (EPR) effect in solid tumor tissue [28]. However, natural exosomes often have low transfection efficiency into eukaryocytes like cancer cells [29]. The increasing uptake efficiency of engineered exosomes was associated with the tLyp-1 peptide which was a cell membrane penetrating peptide [30]. Consequently, this study will provide a high transfection efficiency of targeting tLyp-1 exosomes when they are used as drug or gene delivery vectors for cancer therapy.

3.5. Function verification of targeting siRNA tLyp-1 exosomes in lung cancer cells

To verify the function for gene delivery of targeting tLyp-1 exosomes, three siRNAs (siR1: CCAAGACGCTCATGAAGAA; siR2: GGAGCAGCCGGATTATTA; siR3: GCTCGAGACCTACATGAA) were designed based on the sequence of SOX2 gene, synthesized (Fig. 5A) and encapsulated into the exosomes by electroporation technology. The siRNA encapsulation efficiency of targeting exosomes was 61.53% ± 0.32%, and the siRNA encapsulation efficiency of natural exosomes was 46.87% ± 0.24% (Fig. S2).

The resultant targeting siRNA tLyp-1 exosomes were used to transfect NSCLC A549 cells for knocking-down SOX2 gene. In addition, a commercially available gene delivery vector (lipofectamine) was used as a positive control vector.

To confirm the efficacy of designed siRNAs in knocking-down SOX2 gene, three kinds of siRNAs were separately encapsulated into natural exosomes, targeting tLyp-1 exosomes or lipofectamine, and used for transfecting A549 cells. The mRNA levels of SOX2 gene in the A549 cells after transfection were assessed using real-time qRT-PCR. The results showed that targeting siRNA (siR2) tLyp-1 exosomes had the most significant knock-down effect on SOX2 gene (Fig. 5B), and hence, targeting siRNA (siR2) tLyp-1 exosomes were selected for further study.

To directly observe the transfection efficiency in A549 cells, targeting Cy3 labeled siRNA (siR2) tLyp-1 exosomes were
Fig. 7 – Mechanism illustration of the engineered targeting exosomes for efficient delivery of siRNA into human cancer cells. The tLyp-1-lamp2b plasmid transfected HEK293T cells can secreted tumor targeting tLyp-1 exosomes. By electroporation technology, targeting tLyp-1 exosomes were loaded with siRNA. When targeting tLyp-1 exosome ruptured in cytoplasm, siRNA was loaded into the RNA-induced silencing complex (RISC). The sense (passenger) strand was degraded while the antisense (guide) strand directs RISC to mRNA that has a complementary sequence, thereby resulting in the silencing of target gene. The targeting tLyp-1 exosomes demonstrate highly transfection efficiency in NSCLC cells and highly SOX2 gene silencing ability in NSCLC stem cells.

included for comparing with Cy3 labeled siRNA (siR2) lipo3000, and were evaluated under fluorescent microscope. The results showed that the targeting tLyp-1 exosomes reached the same transfection efficiency as that of lipo3000 by observing Cy3 fluorescent distribution and intensity (Fig. 5C).

The results demonstrated that transfection efficiency of targeting tLyp-1 exosomes was similar to that of commercially available transfection reagents. More importantly, targeting tLyp-1 exosomes have less immunogenic and toxic features [31,32], which assign the favorable characteristics of the engineered targeting tLyp-1 exosomes when they are used as the gene delivery vectors for cancer therapy.

3.6. Function verification of targeting siRNA tLyp-1 exosomes in lung cancer stem cells

To further extend the function of targeting tLyp-1 exosomes for potential future clinical uses, targeting siRNA (siR2) tLyp-1 exosomes were used for transfecting lung cancer stem cells. Accordingly, the lung cancer stem cells were firstly induced by serum-free culture method. The result showed that the lung cancer stem cells could be obtained from the culturing at the 6th day, exhibiting cancer stem cell spheres (Fig. 6A) and up-regulation of stemness gene (CD44+/CD24-).

To verify the efficacy of targeting tLyp-1 exosomes as gene delivery vectors, the lung cancer stem cells were further transfected with targeting siR2 tLyp-1 exosomes. After transfection, the protein expression of SOX2 was evaluated by Western blotting. The results showed that the protein expression of SOX2 in the lung cancer stem cells was significantly knocked-down after 48 h transfection (Fig. 6B).

To reveal the changes in stemness surface makers, CD44 and CD24 markers on the lung cancer stem cells were evaluated by flow cytometry after transfecting with targeting siR2 tLyp-1 exosomes. The results showed that the transfection of targeting siR2 tLyp-1 exosomes resulted in an evident decrease in the population of CD44+/CD24- cells (Fig. 6C).

The results indicate the targeting tLyp-1 exosomes can be used as the gene delivery vectors for effectively transfecting cancer stem cells. As cancer stem cells are characterized as the more resistant malignant cells than cancer cells [33,34], the effective transfection suggests that the targeting tLyp-1 exosomes could be the potential drug delivery carriers for a broad spectrum of anticancer drugs as well.

3.7. Illustration for engineering and mechanism of targeting siRNA tLyp-1 exosomes

For gene therapy, a high efficient delivery vector plays an important role in killing cancer and cancer stem cells. In particular, an effective transfection vector could provide a high efficacy in killing these malignant cells. In this study, the engineering and action mechanism of targeting siRNA tLyp-1 exosomes can be illustrated as the following steps: (i) the engineered tLyp-1-lamp2b plasmids are constructed and amplified in Escherichia coli; (ii) the tLyp-1-lamp2b plasmids are used to transfect HEK293T cells, and the fused protein containing targeting molecule tLyp-1 peptide is successfully expressed in the cells; (iii) the targeting tLyp-1 exosomes are secreted from transfected HEK293T cells; (iv) the artificially synthesized siRNA is encapsulated into
targeting tlyp-1 exosomes by electroporation technology; (v) the targeting siRNA tlyp-1 exosomes are used to transfect cancer or cancer stem cells, and when the exosomes rupture in cytoplasm, siRNA is released from the exosomes and attracted into the RNA-induced silencing complex (RISC); and (vi) consequently, the sense (passenger) strand of siRNA is degraded in cytoplasm while the antisense (guide) strand was combined with a complementary sequence of mRNA within RISC [35], thereby resulting in the knock-down of target gene (such as SOX2 gene in this case) (Fig. 7).

4. Conclusions

In sum, we report a novel targeting tlyp-1 exosome by gene recombinant engineering for delivery of siRNA to cancer and cancer stem cells. The targeting tlyp-1 exosomes have a nanosized structure (approximately 100 nm) and can be produced in large scale by amplification using cell culture technology. The present study reveals the full engineering process of the targeting tlyp-1 exosomes, demonstrates their high transfection efficiency into lung cancer and cancer stem cells, and confirm the functions of targeting siRNA tlyp-1 exosomes in knocking-down the target gene of cancer cells and in decreasing stemness of the cancer stem cells. The results indicate that the targeting tlyp-1 exosomes can be used a powerful gene delivery platform for cancer therapy, and hence are promising for broad potentials in the biomedical fields.

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Acknowledgments

The research leading to these results has received funding from National Natural Science Foundation of China (Grant nos. 81673367 and 81874303) and Beijing Natural Science Foundation (Key Grant no. 7181004).

Supplementary material

Supplementary material associated with this article can be found, in the online version, at doi: 10.1016/j.ajps.2019.04.002.

REFERENCES

[1] Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6(2):244–85.
[2] Chan TS, Hsu CC, Pai VC, Liao WY, Huang SS, Tan KT, et al. Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. J Exp Med 2016;213(13):2967–88.
[3] Hutson TH, Foster E, Moon LD, Yañez-Muñoz RJ. Lentiviral vector-mediated RNA silencing in the central nervous system. Hum Gene Ther Methods 2014;25(1):14–32.
[4] Mulligan RC. The basic science of gene therapy. Science 1993;260(5110):926–32.
[5] Eugene H, Kaji EH, Leiden JM. Gene and stem cell therapies. JAMA 2001;285(5):545–50.
[6] Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494–9.
[7] Naldini L. Ex vivo gene transfer and correction for cell based therapies. Nat Rev Genet 2011;12(5):301–15.
[8] Kim CS, Duncan B, Creran B, Rotello VM. Triggered nanoparticles as therapeutics. Nano Today 2013;8(4):439–47.
[9] Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002;2(8):569e79.
[10] Théry, C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009;9(8):581e93.
[11] Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosomes mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9(6):565e9.
[12] Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 2010;18(9):1606–14.
[13] Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014;35(7):2383–90.
[14] Wahlgren J, De L Karlson T, Brisslert M, Vaziri Sani F, Telemo E, Sunnerhagen P, et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 2012;40(17):e130.
[15] Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1 dependent cell, vascular and tissue penetration. Proc Natl Acad Sci USA 2009;106(38):16157–62.
[16] Kawakami T, Tokunaga T, Hatanaka H, Kijima H, Yamazaki H, Abe Y, et al. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 2002;95(10):2196–201.
[17] Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, et al. Transstumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 2012;31(33):3754–63.
[18] Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M, Koeppen H. Neuropilin-1 expression in cancer and development. J Pathol 2012;226(1):50–60.
[19] Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, et al. Transstumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 2012;31(33):3754–63.
[20] Melmikova I. RNA-based therapies. Nat Rev Drug Discov 2007;6(11):863–4.
[21] Saretz SM, Werfel TA, Lee L, Jackson MA, Kilchrist KV, Brantley-Sieders D, et al. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Proc Natl Acad Sci USA 2017;114(32):E6490–7.
[22] Soutschek J, Akinc A, Bramlage B, Charissis K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous...
gene by systemic administration of modified siRNAs. Nature 2004;432(7014):173–8.

[23] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta CT}$ method. Methods 2001;25:402–8.

[24] Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomallike vesicles are present in human blood plasma. Int Immunol 2005;17(7):879–87.

[25] Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 2001;25:402–8.

[26] Syn NL, Wang L, Chow EK, Lim CT, Goh BC. Exosomes: from garbage bins to promising therapeutic targets. Int J Mol Sci 2017;18(3):E538.

[27] Hadla M, Palazzolo S, Corona G, Caligiuri I, Canzonieri V, Toffoli G, et al. Exosomes: the next generation of endogenous nanomaterials for advanced drug delivery and therapy. Acta Biomater 2018;28(18):S1742–7061.

[28] Biswas S, Torchilin VP. Nanopreparations for organelle-specific delivery in cancer. Adv Drug Deliv Rev 2014;66:26–41.